Value Sense
SMMT
Summit Therapeutics Inc. (SMMT)
Last Price$19.1(7.5%)
Market Cap$14.6B
LTM Net Debt
($405.1M)
YoY Growth
+405.5%
3Y CAGR
+80.0%
5Y CAGR
+52.7%
Stock quality & Intrinsic value
6/10
97.4% overvalued
SMMT
is (97.4%) overvalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

Summit Therapeutics Inc. Net Debt

Annual
Quarterly
LTM
Crunching data... Almost there!
Jan'06Jan'07Jan'08Jan'09Jan'10Jan'11Jan'12Jan'13Jan'14Jan'15Jan'16Jan'17Jan'18Jan'19Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24
Net Debt
($37.7M)
($67.9M)
($34.3M)
($2,925.9K)
($15.5M)
($8,236.4K)
($5,138.1K)
($8,462.5K)
($5,502.9K)
($25.5M)
($33.1M)
($44.1M)
($63.4M)
($46.2M)
($64.5M)
($66.0M)
($69.4M)
$170.2M
($80.1M)
($405.1M)
SMMT
Key metrics and insights to make informed decisions.
View full analysis
Overvalued or undervalued?
Check the intrinsic value for SMMT and see if it's the right time to invest.
Dive in

Summit Therapeutics Inc. (SMMT) Net Debt comparison analysis

General

LTM Net Debt

Growth

Company name

YoY growth

3Y CAGR

5Y CAGR

Summit Therapeutics Inc. logo
Summit Therapeutics Inc.SMMT
($405.1M)
405.5%
80.0%
61.5%
Median Peer Set
($1,857.5M)
0.0%
1.1%
7.3%
Novo Nordisk A/S logo
Novo Nordisk A/SNVO
$10.6B
N/A
102.9%
N/A
Royalty Pharma plc logo
Royalty Pharma plcRPRX
($929.0M)
N/A
N/A
N/A
Alnylam Pharmaceuticals, Inc. logo
Alnylam Pharmaceuticals, Inc.ALNY
($1,398.5M)
N/A
77.5%
7.9%
BeiGene, Ltd. logo
BeiGene, Ltd.BGNE
($1,600.5M)
(38.3%)
(20.6%)
11.3%
Incyte Corporation logo
Incyte CorporationINCY
($2,114.5M)
(41.6%)
(2.8%)
0.4%
United Therapeutics Corporation logo
United Therapeutics CorporationUTHR
($2,967.0M)
29.3%
2.2%
16.2%
Vertex Pharmaceuticals Incorporated logo
Vertex Pharmaceuticals IncorporatedVRTX
($4,366.4M)
(54.9%)
(12.7%)
6.8%
Regeneron Pharmaceuticals, Inc. logo
Regeneron Pharmaceuticals, Inc.REGN
($15.9B)
95.6%
20.5%
22.6%
BioNTech SE logo
BioNTech SEBNTX
($18.3B)
10.1%
98.4%
104.2%
argenx SE logo
argenx SEARGX
N/A
N/A
N/A
N/A

SMMT key stats

USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Jan'06Jan'07Jan'08Jan'09Jan'10Jan'11Jan'12Jan'13Jan'14Jan'15Jan'16Jan'17Jan'18Jan'19Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24
Revenue
% growth
1.7
338.9%
3.8
119.8%
12.1
219.9%
0.5
(96.0%)
0.5
(1.1%)
1.9
290.6%
4.4
138.3%
4.6
2.5%
3.6
(21.8%)
3.7
4.3%
0.0
(100.0%)
3.9
0.0%
46.8
1,114.8%
74.9
59.9%
0.8
(98.9%)
0.9
6.6%
1.8
110.3%
0.7
(61.1%)
0.0
(100.0%)
0.0
0.0%
Cost of Goods Sold (COGS)0.81.15.00.00.00.01.60.00.00.00.00.00.10.00.20.00.02.52.115.0
Gross Profit
% margin
1.0
56.1%
2.7
70.6%
7.0
58.3%
0.5
97.8%
0.5
100.0%
1.9
100.0%
2.8
63.7%
4.6
100.0%
3.6
100.0%
3.7
100.0%
0.0
0.0%
3.9
100.0%
46.7
99.7%
74.8
100.0%
0.6
75.4%
0.9
100.0%
1.8
100.0%
(1.8)
(257.0%)
(2.1)
0.0%
(15.0)
0.0%
Operating Expenses6.818.653.927.915.08.611.913.520.931.644.845.470.463.353.653.288.064.387.7211.3
Research & Development Expenses (R&D)3.310.830.713.35.85.77.79.117.025.636.431.753.468.241.753.385.452.059.5150.8
Selling, General & Administrative Expenses (SG&A)3.23.514.69.16.64.13.74.45.111.111.313.822.121.511.919.223.626.728.260.5
Operating Income
% margin
(5.8)
(338.9%)
(16.0)
(423.8%)
(46.9)
(388.4%)
(34.7)
(7,198.9%)
(14.5)
(3,047.6%)
(14.5)
(777.1%)
(7.6)
(170.1%)
(11.5)
(252.3%)
(17.4)
(487.9%)
(31.3)
(844.4%)
(43.7)
0.0%
(41.6)
(1,078.7%)
(23.7)
(50.7%)
16.4
21.9%
(54.6)
(6,766.4%)
(53.2)
(6,185.2%)
(86.2)
(4,764.3%)
(72.1)
(10,235.6%)
(89.7)
0.0%
0.3
0.0%
Interest Income1.93.23.10.80.00.00.00.00.00.00.00.05.74.90.00.00.21.510.40.0
Interest Expense0.00.00.20.20.20.00.00.00.00.70.01.42.10.70.00.30.34.416.5(8.7)
Pre-tax Income(3.9)(12.8)(43.9)(34.2)(14.7)(14.4)(7.5)(11.5)(17.3)(31.2)(43.7)(43.0)(20.1)8.8(36.3)(52.9)(88.6)(78.8)(615.9)(221.3)
Income Tax
% effective tax rate
(0.5)
12.8%
(1.8)
13.9%
(3.6)
8.3%
(4.6)
13.3%
(0.9)
6.4%
(3.0)
20.7%
(0.8)
10.1%
(0.9)
7.5%
(1.6)
9.1%
(3.2)
10.2%
(6.6)
15.2%
(7.3)
16.9%
(6.9)
34.5%
(4.3)
(49.6%)
(5.8)
15.9%
(0.2)
0.4%
(2.5)
2.8%
(4.4)
5.6%
(0.9)
0.2%
0.0
0.0%
Net Income
% margin
(3.4)
(199.7%)
(11.0)
(292.1%)
(40.3)
(334.1%)
(58.4)
(12,109.8%)
(13.7)
(2,867.2%)
(11.4)
(614.7%)
(6.8)
(152.6%)
(10.6)
(232.9%)
(15.8)
(443.1%)
(28.0)
(754.9%)
(37.0)
0.0%
(35.7)
(927.6%)
(13.1)
(28.1%)
13.1
17.5%
(30.5)
(3,779.1%)
(52.7)
(6,127.6%)
(86.1)
(4,762.1%)
(74.4)
(10,561.1%)
(614.9)
0.0%
(221.3)
0.0%
EPS(0.11)(0.30)(0.84)(1.09)(0.21)(0.07)(0.04)(0.67)(3.26)(0.70)(0.62)(0.58)(0.21)0.15(0.19)(0.76)(0.93)(0.38)(0.99)(0.31)
Diluted EPS(0.11)(0.30)(0.84)(1.09)(0.21)(0.07)(0.04)(0.67)(3.26)(0.70)(0.62)(0.58)(0.20)0.15(0.19)(0.76)(0.93)(0.38)(0.99)(0.31)
EBITDA
% margin
(5.4)
(313.6%)
(11.4)
(302.4%)
(37.2)
(308.4%)
(29.0)
(6,010.3%)
(8.5)
(1,790.5%)
(13.3)
(716.0%)
(7.1)
(159.0%)
(8.7)
(191.3%)
(17.3)
(486.0%)
(20.0)
(537.9%)
(30.9)
0.0%
(41.5)
(1,075.8%)
(41.9)
(89.5%)
15.5
20.7%
(21.4)
(2,657.4%)
(37.1)
(4,317.9%)
(62.7)
(3,468.0%)
(52.6)
(7,472.8%)
1.0
0.0%
0.3
0.0%

Discover more Stock Ideas

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks

Undervalued growth stocks

Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
More ideas -->

FAQ

1) What is Summit Therapeutics Inc.'s Net Debt?

As of today, Summit Therapeutics Inc.'s last 12-month Net Debt is ($405.1M), based on the financial report for Dec 31, 2024 (Q4’2024).

2) What is Summit Therapeutics Inc.'s Net Debt growth rate?

Over the last year, Summit Therapeutics Inc.'s Net Debt growth was 405.5%. The average annual Net Debt growth rates for Summit Therapeutics Inc. have been 58.8% over the past three years, 52.7% over the past five years.

3) Is Summit Therapeutics Inc.'s Net Debt growth rate Good?

Over the last year, Summit Therapeutics Inc.'s Net Debt growth was 405.5%, which is higher than industry growth of (0.1%). It indicates that Summit Therapeutics Inc.'s Net Debt growth is Bad.

4) How does Summit Therapeutics Inc.'s Net Debt growth rate compare to its peers?

Over the last year, Summit Therapeutics Inc.'s Net Debt growth was 405.5%, which is higher than peer median growth of (24.0%). The list of peers includes NVO, RPRX, ALNY, BGNE, INCY, UTHR, VRTX, REGN, BNTX, ARGX etc.